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ABSTRACT: Ribosomally synthesized and post-transla-
tionally modiﬁed peptides are a rapidly expanding class of
natural products. They are typically biosynthesized by
modiﬁcation of a C-terminal segment of the precursor
peptide (the core peptide). The precursor peptide also
contains an N-terminal leader peptide that is required to
guide the biosynthetic enzymes. For bioengineering
purposes, the leader peptide is beneﬁcial because it allows
promiscuous activity of the biosynthetic enzymes with
respect to modiﬁcation of the core peptide sequence.
However, the leader peptide also presents drawbacks as it
needs to be present on the core peptide and then removed
in a later step. We show that fusing the leader peptide for
the lantibiotic lacticin 481 to its biosynthetic enzyme LctM
allows the protein to act on core peptides without a leader
peptide. We illustrate the use of this methodology for
preparation of improved lacticin 481 analogues containing
non-proteinogenic amino acids.
C
yclic peptides are attracting increased attention for their
potential pharmaceutical applications. They are metabol-
ically more stable than linear peptides and are promising
candidates for disruption of protein−protein interactions.
Natural product cyclic peptides are generated by both non-
ribosomal
1,2 and ribosomal pathways.
3 The molecules produced
by the latter route have rapidly expanded in both number and
structural diversity in recent years as a consequence of the
explosion in genomic sequence information.
4,5 These pathways,
in which a linear precursor peptide is generated ribosomally and
subsequently post-translationally modiﬁed, provide many
attractive opportunities for bioengineering. First, the amino
acid sequence is genetically encoded, allowing site-directed
mutagenesis approaches to access analogues. Second, the
pathways toward these compounds usually involve a relatively
small number of biosynthetic enzymes, which often act
iteratively. In turn, such short pathways are more amenable
to bioengineering approaches. Third, the biosynthetic enzymes
are often highly promiscuous, achieved in part by a biosynthetic
strategy in which the enzymes recognize an N-terminal leader
peptide that activates them toward catalyzing post-translational
modiﬁcations of the C-terminal core peptide that will become
the natural product (e.g., Figure 1).
6
Because the biosynthetic enzymes for these ribosomally
synthesized cyclic peptides typically recognize the leader
peptide, the sequence of the core peptide is often hyper-
variable.
7−10 The post-translational modiﬁcations release these
natural products from the structural and functional constraints
imposed on natural ribosomal peptides, while at the same time
restricting conformational ﬂexibility to allow better target
recognition and increased metabolic and chemical stability. An
example of such a system is shown in Figure 1 for lacticin 481, a
member of the lantibiotic group of polycylic peptides. A single,
multifunctional enzyme LctM repeatedly dehydrates Ser and
Thr residues in the core peptide to generate the dehydroamino
acids dehydroalanine (Dha) and dehydrobutyrine (Dhb),
respectively.
11 The enzyme subsequently catalyzes conjugate
additions of Cys residues to the α,β-unsaturated structures.
12
The attractive attributes of ribosomally synthesized cyclic
peptides have not gone unnoticed, and a large number of
studies have focused on using site-directed mutagenesis to
improve their properties.
15−20 Recently, these studies were
extended to substitutions with non-proteinogenic amino acids
in Escherichia coli.
21−23 In addition, an increasing number of
these biosynthetic pathways has been reconstituted in
vitro,
8,12,24−30 which has enabled the combination of promis-
cuous biosynthetic enzymes with the power of peptide
synthesis to generate molecular diversity.
31 A major current
limitation of the latter approach is that the leader peptide needs
to be attached to synthetic core peptides, which has been
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Figure 1. Biosynthesis of lacticin 481. The leader is proteolytically
removed from the modiﬁed core peptide by a bifunctional protease/
transporter enzyme (LctT). Although the process is drawn as
complete dehydration by the bifunctional synthetase LctM before
the commencement of cyclization, recent studies suggest the
dehydration and cyclization events may be alternating.
13,14
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31−33 After
post-translational modiﬁcation, the leader needs to be removed,
typically with a commercial protease
8,12,29,34,35 or using
photochemically labile linkers.
36 The overall process is
ineﬃcient and does not render this strategy readily amenable
for use with combinatorial peptide libraries.
In an attempt to overcome the disadvantages of leader
peptide attachment and subsequent removal, we explored
whether addition of the leader and core peptides in trans would
result in eﬃcient catalysis. In previous work, this approach was
only partially successful for lacticin 481, resulting in
incompletely processed core peptides when the leader and
core peptides were present in low concentrations.
37 In this
investigation, we increased the concentrations of synthetic
leader peptide, which resulted in products that were three- or
four-fold dehydrated as determined by matrix-assisted laser
desorption/ionization mass spectrometry (MALDI-MS) (Fig-
ure 2). All core peptides in this study contained an Asn15Arg
mutation previously identiﬁed as being beneﬁcial for solubility
without compromising antimicrobial activity.
38 The four-fold
dehydrated core peptide was puriﬁed by HPLC (Figures S1,
S2) and did not react with 1-cyano-4-dimethylamino
pyridinium tetraﬂuoroborate (CDAP), a thiol-selective electro-
phile, indicating that the three Cys residues underwent the
desired Michael additions. When the product was used for
antimicrobial assays against Lactococcus lactis HP, its activity
and that of an authentic sample puriﬁed from the producer
strain (L. lactis CNRZ 481, see Supporting Information) were
very similar. Thus, LctM can convert the core peptide of LctA
into lacticin 481 when the leader peptide is provided in trans.
The successful production of lacticin 481 from a leaderless
core peptide was encouraging, as it would no longer require
ligation of the leader peptide to synthetic core peptides.
However, the overall process is ineﬃcient with regard to atom
economy as it requires relatively large concentrations of the
synthetic leader peptide. We envisioned that this disadvantage
could potentially be overcome by attaching the leader sequence
of the LctA substrate to the LctM biosynthetic enzyme by
fusing their gene sequences. Activation of LctM by leader
peptide binding is believed to shift the equilibrium of active and
inactive conformations from predominantly inactive in the
absence of the leader peptide, to predominantly active in its
presence (Figure 3A).
39 This model suggested that attachment
of the leader peptide to LctM (Figure 3B) would result in a
high eﬀective molarity and more eﬃcient catalysis than
providing core and leader peptides in trans, thus yielding a
constitutively active fusion (ConFusion) enzyme. In addition,
the leader peptide would not need to be synthesized
independently as it would be obtained during enzyme
expression in E. coli. A related approach fused the NS3
protease/helicase involved in processing the hepatitis C virus
polyprotein to a portion of its activator protein, resulting in a
constitutively active protease.
40
To test the hypothesis, several heterologous expression
constructs were generated that encoded a hexa-His-tagged LctA
leader peptide fused to the N-terminus of the LctM synthetase
via a (GlySer)n linker sequence (n = 1, 5, 10, and 15; Figure S3;
longer linkers decreased protein expression yields) to generate
the LctM ConFusion enzyme (LctCE-GSn). The hybrid genes
were subcloned into a pET28b vector and overexpressed in E.
coli, and the resulting fusion proteins were puriﬁed by
immobilized metal aﬃnity chromatography (IMAC). Incuba-
tion of the core peptide of LctA, obtained by solid-phase
peptide synthesis, with LctCE-GSG, ATP, and Mg2+ resulted in
dehydration activity as demonstrated by MALDI-MS. The
desired four-fold dehydrated core peptide was observed as a
minor product along with intermediates that underwent one,
two, and three dehydrations (Figure 4). Reactions utilizing
LctCE-GS5, LctCE-GS10, or LctCE-GS15 resulted in progres-
sively more eﬃcient dehydration such that with LctCE-GS15,
the four-fold dehydrated core peptide was the major product
(Figure 4). After 1 h, signiﬁcant amounts of an intermediate
with three dehydrations and one phosphorylation were still
present, but this intermediate is mostly converted to four-fold
dehydrated product by 180 min (Figure S4). Furthermore,
HPLC analysis, CDAP assays, and bioactivity assays (vide infra)
demonstrated that the three thioether rings were formed in the
four-fold dehydrated product, demonstrating LctCE-GS15 to be
constitutively active. The protein was obtained in 10 mg/L of E.
coli cell culture without any optimization of culturing and
expression conditions.
Figure 2. Eﬀect of leader peptide concentration on the in trans
processing of the LctA core peptide by LctM. Shown are MALDI-TOF
mass spectra of the LctA core peptide after a 3 h incubation. The ﬁnal
concentrations of the core peptide and enzyme were 20 μM and 2 μM,
respectively. Numbers above the peaks indicate the number of
dehydrations; an asterisk indicates a phosphorylated substrate; SM
indicates starting material.
Figure 3. (A) The leader peptide is believed to trap an active
conformation of the enzyme that is present as a minor fraction in the
absence of the leader peptide. (B) Proposed model of a constitutively
active lacticin 481 synthetase. The LctA leader peptide (red) is
covalently fused to the synthetase via a ﬂexible proteinogenic linker
(purple). As with the model in panel A, it was envisioned that the
leader peptide would shift the equilibrium population toward the
active enzyme species, thereby enabling the modiﬁcation of LctA core
peptide (green).
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process of the core peptide catalyzed by LctCE-GS15 and by
wild-type LctM with a synthetic leader peptide provided in
trans were evaluated using a combination of HPLC and
MALDI-MS. The modiﬁcation assays were carried out at a 10:1
substrate:enzyme ratio (ﬁnal concentrations 20 μM substrate
and 2 μM enzyme). In the assay with His6-LctM, the LctA
leader peptide was supplemented at the same concentration as
the synthetase enzyme, thus mimicking the ConFusion enzyme
where the leader and synthetase enzyme are present in
stoichiometric equivalents. Under conditions in which the
leader peptide was provided in trans, the fully modiﬁed lacticin
481 core peptide was a minor product in the LctM-catalyzed
reaction after 3 h. In contrast, with the ConFusion enzyme
LctCE-GS15 the four-fold dehydrated peptide was the major
product (Figure S5). Importantly, after puriﬁcation of this four-
fold dehydrated peptide, the antimicrobial activity of the
product was comparable to lacticin 481 isolated from the
producer organism.
The observation that the LctCE-GS15 enzyme correctly
breaks eight chemical bonds and generates six new chemical
bonds in the core peptide without the need for a leader peptide
on the substrate demonstrates that a covalent bond between
the leader and core peptides is not required for ensuring the
correct regiochemistry of cyclization. These results also suggest
that the enzyme must have binding aﬃnity for the core peptide.
A similar conclusion was reached recently by the observation
that pull-down of the dehydratase NisB and cyclase NisC
involved in the biosynthesis of the lantibiotic nisin required the
full-length substrate peptide including the core peptide.
41 Our
results also rule out any model in which the leader peptide is
used to pull the core peptide through the active site of LctM for
directional processing.
This methodology overcomes two key limitations of in vitro
biosynthesis of lantibiotics: the eﬀorts required to attach the
leader peptide to analogues of core peptides that contain non-
proteinogenic amino acids, and the challenges associated with
leader peptide removal during the ﬁnal steps of lantibiotic
maturation. Most of the native proteases that remove leader
peptides from ribosomally synthesized peptide natural products
are either unknown or are membrane-bound proteins. There-
fore, leader peptide removal for in vitro bioengineering studies
has been achieved predominantly by mutagenesis of the
precursor peptide to include commercial protease recognition
sites.
8,29,35 Unfortunately, these mutations can have deleterious
eﬀects, including reduced heterologous expression levels,
diminished or even abolished precursor peptide processing by
the biosynthetic enzymes, and non-speciﬁc proteolytic cleavage
after modiﬁcation of the core peptide.
To test the generality of the ConFusion enzyme technology,
several analogues of lacticin 481 were prepared. Wild-type
lacticin 481 demonstrates sub-micromolar inhibitory activity
(IC50 = 750 nM) against L. lactis HP.
31 Previous studies have
suggested that substitution of Trp19 and/or Phe21 with non-
proteinogenic amino acids improves the antimicrobial activity
of lacticin 481.
31 However, the proteolytic step necessary to
remove the leader peptide in these studies resulted in lacticin
481 analogues missing the N-terminal lysine, which is
important for activity.
31 Because a proteolytic step is not
required to produce lacticin 481 analogues using LctCE, the
products would include this important residue. Four mutants of
the LctA core peptide were prepared by Fmoc-based solid-
phase peptide synthesis containing the following mutations:
N15R/F21H, N15R/F21Pal, N15R/W19Nal/F21H, and
N15R/W19Nal/F21Pal (Pal = 3-(4′-pyridyl)alanine, Nal = 3-
(2-naphthyl)alanine; Figure S6). The four mutant core peptides
were treated with puriﬁed His6-LctCE-GS15 in the presence of
Mg2+ and ATP. Fully modiﬁed product was generated in each
reaction with the eﬃciency comparable to that observed with
the wild-type core peptide. Partially processed intermediates
were readily separated from the desired product via reversed-
phase HPLC (Figure S7), and the fully modiﬁed material was
analyzed for antimicrobial activity against L. lactis HP. The IC50
for authentic lacticin 481 was 785 ± 19 nM, agreeing well with
a previously reported value (750 nM).
31 Interestingly, lacticin
481 N15R/F21Pal and lacticin 481 N15R/F21H displayed
greater inhibitory activity compared to authentic lacticin 481
with IC50 values of 213 ± 9 and 428 ± 21 nM, respectively. The
triply substituted analogues were not as active as authentic
lacticin 481 under the conditions tested (IC50 values of 1370 ±
48 nM for N15R/F21H/W23Nal and 2420 ± 60 nM for
N15R/F21Pal/W23Nal). Thus, improved analogues of lacticin
481 can be prepared using this strategy.
The ConFusion approach allows relatively rapid evaluation of
synthetic peptides. When hits with improved antimicrobial
activity are identiﬁed, follow-up studies can focus on generating
these analogues in larger amounts by heterologous expression
in E. coli using stop-codon suppression methodology
42 or
auxotrophic strains. The successful application of such
methodology was recently illustrated for the prochlorosins
and lichenicidins, class II lanthionine containing peptides,
21,23
and for the cyanobactins, another group of post-translationally
modiﬁed peptide natural products.
22 Furthermore, in the past
year, 11 diﬀerent lantibiotics have been successfully produced
in E. coli in several laboratories,
21,23,43−45 illustrating the
generality of this approach. However, lacticin 481 has not yet
been produced in E. coli. We therefore constructed a pDUET
co-expression vector containing LctM and His6-LctA to test
production of lacticin 481 in E. coli BL21 (DE3). After
induction of expression with IPTG, harvesting of the cells, lysis,
and IMAC puriﬁcation, His6-LctA was obtained that had been
completely processed (four dehydrations and three cycliza-
tions). Removal of the leader peptide with LysC resulted in the
desired compound as shown by HPLC, MS, and bioactivity
assays (Figure S8). LysC was used in this ﬁnal step instead of
Figure 4. Eﬀect of linker length on the processing of the core peptide
by a series of lacticin 481 ConFusion enzymes. Shown are MALDI-
TOF mass spectra of the LctA core peptide after 1 h of incubation.
Indicated to the right of the spectra is the enzyme utilized for the
reaction. The ﬁnal concentrations of substrate and enzyme were 20
μM and 2 μM, respectively. Numbers above the peaks indicate the
number of dehydrations. Asterisk indicates phosphorylated substrate;
SM = starting material.
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peptide in the producer strain. Although the activity of the
protease domain of LctT has been reconstituted in vitro,
46 it
possesses very low eﬃciency.
In summary, this work illustrates a platform that can rapidly
transform synthetic peptides into polycylic products to be
evaluated for biological activity. Because of the modularity of
peptide synthesis, this methodology enables SAR studies that
can cover a much larger chemical space than conventional site-
directed mutagenesis. Once hits are identiﬁed, the tools are
available to achieve and optimize larger-scale production of the
compounds in E. coli.
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